The estimated Net Worth of Daniel C. Martin is at least 2.64 百万$ dollars as of 15 February 2024. Mr Martin owns over 2,267 units of Deciphera Pharmaceuticals Inc stock worth over 1,410,470$ and over the last 6 years he sold DCPH stock worth over 526,645$. In addition, he makes 707,823$ as Sr. VP & Chief Commercial Officer at Deciphera Pharmaceuticals Inc.
Sign up
Mr Martin DCPH stock SEC Form 4 insiders trading
Mr has made over 12 trades of the Deciphera Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 2,267 units of DCPH stock worth 35,411$ on 15 February 2024.
The largest trade he's ever made was exercising 26,999 units of Deciphera Pharmaceuticals Inc stock on 22 January 2020 worth over 974,664$. On average, Mr trades about 3,830 units every 101 days since 2018. As of 15 February 2024 he still owns at least 55,118 units of Deciphera Pharmaceuticals Inc stock.
You can see the complete history of Mr Martin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Daniel C. Martin biography
Daniel C. Martin is the Sr. VP & Chief Commercial Officer at Deciphera Pharmaceuticals Inc.
What is the salary of Mr Martin?
As the Sr. VP & Chief Commercial Officer of Deciphera Pharmaceuticals Inc, the total compensation of Mr Martin at Deciphera Pharmaceuticals Inc is 707,823$. There are 12 executives at Deciphera Pharmaceuticals Inc getting paid more, with Steven Hoerter having the highest compensation of 9,025,190$.
How old is Mr Martin?
Mr Martin is 46, he's been the Sr. VP & Chief Commercial Officer of Deciphera Pharmaceuticals Inc since . There are 19 older and 1 younger executives at Deciphera Pharmaceuticals Inc. The oldest executive at Deciphera Pharmaceuticals Inc is Edward Benz, 73, who is the Independent Director.
What's Mr Martin's mailing address?
Daniel's mailing address filed with the SEC is C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM, MA, 02451.
Insiders trading at Deciphera Pharmaceuticals Inc
Over the last 7 years, insiders at Deciphera Pharmaceuticals Inc have traded over 25,274,872$ worth of Deciphera Pharmaceuticals Inc stock and bought 3,916,644 units worth 57,831,028$ . The most active insiders traders include Liam Ratcliffe、Associates Llc Brightstar、Ron Squarer. On average, Deciphera Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of 1,218,775$. The most recent stock trade was executed by Thomas Patrick Kelly on 15 February 2024, trading 3,010 units of DCPH stock currently worth 47,016$.
What does Deciphera Pharmaceuticals Inc do?
deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.
What does Deciphera Pharmaceuticals Inc's logo look like?
Complete history of Mr Martin stock trades at Deciphera Pharmaceuticals Inc
Deciphera Pharmaceuticals Inc executives and stock owners
Deciphera Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Steven Hoerter,
President, Chief Executive Officer, Director -
Michael Taylor,
Director -
Matthew Sherman,
Executive Vice President, Chief Medical Officer -
Thomas Kelly,
Chief Financial Officer, Executive Vice President, Treasurer -
Steven L. Hoerter,
Pres, CEO & Director -
Daniel Flynn,
Founder, Executive Vice President, Chief Scientific Officer -
Dr. Matthew L. Sherman,
Exec. VP & Chief Medical Officer -
Ron Squarer,
Independent Director -
Frank Friedman,
Independent Director -
Thomas Patrick Kelly J.D.,
Exec. VP, CFO & Treasurer -
Dr. Matthew L. Sherman M.D.,
Exec. VP & Chief Medical Officer -
Dr. Daniel L. Flynn,
Exec. VP, Chief Scientific Officer & Founder -
Daniel C. Martin,
Sr. VP & Chief Commercial Officer -
Dr. Stephen B. Ruddy Ph.D.,
Sr. VP & Chief Technical Officer -
Susan Kelley,
Independent Director -
James Bristol,
Independent Chairman of the Board -
Edward Benz,
Independent Director -
Patricia Allen,
Independent Director -
Dennis Walsh,
Independent Director -
John Martin,
Independent Director -
Melissa Forst,
IR Contact Officer -
Lisa Amaya Price,
Sr. VP & Chief HR Officer -
Jennifer Larson,
Sr. VP of Fin. & Investor Relations -
Margarida Duarte,
Sr. VP & Head of International -
Jama Pitman,
Sr. VP of Regulatory, Quality & Portfolio Management -
Jeffrey M. Held J.D.,
Sr. VP & Gen. Counsel -
Jennifer Robinson,
VP of Investor Relations -
Dashyant Dhanak,
EVP & Chief Scientific Officer -
Leaf Venture Management Iii...,
-
Liam Ratcliffe,
Director -
Associates Llc Brightstar,
10% owner -
Christopher John Morl,
Chief Business Officer -
Michael Jay Ross,
Director -
Oliver Rosen,
Chief Medical Officer -
Stephen B. Ruddy,
Chief Technical Officer -
Daniel C. Martin,
Chief Commercial Officer -
Jama Pitman,
SVP, Chief Development Officer